Find Clinical Trial

A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in combination with various standard treatments including hormonal and cytotoxic agents


← Back
Study Phase

Phase 1-2

Therapeutic Area

Cancers

Active substance/
Medical device

S064315

SponsorInstitut de Recherches Internationales Servier
Active Substance CodeS064315
Protocol CodeCL1-64315-003
EudraCT Code2019-000998-23


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility